What is Gonadorelin?
Gonadorelin is gonadotropin-releasing hormone. A clinical series studied pulsatile administration in women with hypothalamic amenorrhea, a specific reproductive-hormone disorder.
Biological role or research focus
Hypothalamic amenorrhea and fertility physiology.
These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
Role reference: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗
Names you may encounter
GnRH-I
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Gonadotropin-releasing hormone decapeptide
- Research focus
- Hypothalamic amenorrhea and fertility physiology
- Featured evidence
- Human clinical series
- Source check
- October 4, 2026
Quick answers
- Is Gonadorelin FDA approved?
- It was approved but is no longer marketed. Factrel (NDA 018123, approved 1982, diagnostic) and Lutrepulse (NDA 019687) are both listed in Drugs@FDA as discontinued; no gonadorelin product is currently marketed in the US. Source ↗
- Is Gonadorelin safe?
- Gonadorelin was once FDA-approved (Factrel, Lutrepulse) but no human product is marketed in the US now; no current label exists, and safety data come from older studies and case reports. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Gonadorelin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Multicenter pulsatile GnRH clinical series (1990) | Human clinical series | 109 women with primary or secondary hypothalamic amenorrhea. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human clinical series · 1990
Multicenter pulsatile GnRH clinical series
What outcomes were reported with pulsatile GnRH in hypothalamic amenorrhea?
- Population / model
- 109 women with primary or secondary hypothalamic amenorrhea.
- Study design
- Multicenter clinical series of pulsatile GnRH treatment; the abstract does not describe a randomized placebo-controlled comparison.
- Main finding
- Reported ovulation rates were 91% in primary and 96% in secondary amenorrhea. Multiple pregnancies occurred in 12%; intravenous-line complications averaged 7%.
- Limits & context
- These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Gonadorelin as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Premenstrual syndrome. ↗
BMJ clinical evidence · 2007 May 1 · Journal Article, Systematic Review
Breast pain. ↗
BMJ clinical evidence · 2011 Jan 17 · Journal Article, Systematic Review
Read available full text ↗
Endometriosis. ↗
BMJ clinical evidence · 2007 Mar 1 · Journal Article, Systematic Review
Read available full text ↗
Endometriosis. ↗
BMJ clinical evidence · 2010 Aug 13 · Journal Article, Systematic Review
Read available full text ↗
Risks & interactions
Gonadorelin was once FDA-approved (Factrel, Lutrepulse) but no human product is marketed in the US now; no current label exists, and safety data come from older studies and case reports.
We found no archived FDA label; Drugs@FDA lists Factrel and Lutrepulse as discontinued. Evidence comes from older clinical series, such as a 1990 trial in 109 women, and case reports. Modern, controlled safety data are lacking.
No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.
Serious risks
- Multiple pregnancy when used to trigger ovulation (about one in eight in one trial)
- Complications from the intravenous line used to give it
- Severe allergic reactions, including anaphylaxis, in rare case reports
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Drugs@FDA: Factrel, NDA 018123 (discontinued) ↗ · Drugs@FDA: Lutrepulse, NDA 019687 (discontinued) ↗ · Santoro, Am J Obstet Gynecol 1990: efficacy and safety of Lutrepulse ↗ · Akin et al., J Pediatr Endocrinol Metab 2015: anaphylaxis to gonadorelin acetate ↗ · Foster et al., Am J Obstet Gynecol 1989: IgE hypersensitivity to gonadorelin (Factrel) ↗
What the featured evidence can tell us
Multiple pregnancy and intravenous-line complications were reported. The study cannot establish safety or benefit for unrelated reproductive disorders.
Identity, route, and evidence limits
These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
Regulatory status
- U.S. FDA approval
- Approved, now discontinued
Factrel (NDA 018123, approved 1982, diagnostic) and Lutrepulse (NDA 019687) are both listed in Drugs@FDA as discontinued; no gonadorelin product is currently marketed in the US. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named explicitly ("gonadotrophin-releasing hormone (GnRH, gonadorelin)"); prohibited in males. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical context & research status
The selected report concerns specialist fertility treatment in hypothalamic amenorrhea. It does not establish general testosterone enhancement or fertility improvement across all causes.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
How Gonadorelin works
The timing of GnRH signaling matters. Pulsatile replacement and sustained stimulation by a long-acting analogue can produce different endocrine effects; the names cannot be treated as interchangeable interventions.
Molecular structure
Questions worth asking
- Is pulsatile gonadorelin equivalent to a long-acting GnRH agonist?
- What population, comparator, and route were actually studied?
- These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is pulsatile gonadorelin equivalent to a long-acting GnRH agonist?
No. Pulsatile signaling can stimulate reproductive hormone release, whereas sustained agonist exposure may suppress the pathway. Clinical purpose and timing matter.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
